Results 101 to 110 of about 49,826 (161)

Beneficial Effects of Canagliflozin in Heart Failure Associated With Cardiac and Surgical Procedures. [PDF]

Rev Cardiovasc Med
Dong Y, Zhou F, Chi L, Mu J.
europepmc   +1 more source

Blood Pressure-Lowering Effect of SGLT2 Inhibitors in Patients Without Antihypertensive Treatment: A Real-World Data Analysis. [PDF]

J Clin Hypertens (Greenwich)
Ito R, Satoh M, Hashimoto H, Nobayashi H, Izumi S, Toyama M, Iwabe Y, Suzuki Y, Hirose T, Nakayama S, Murakami T, Sasaki M, Metoki H.   +12 more
europepmc   +1 more source

Bioinformatics study of the pharmacological mechanism of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus and coronary heart disease based on network pharmacology. [PDF]

Medicine (Baltimore)
Yu S, Li J, Wu X, Lu S, Li C, Cheng H, Guo H, Yang P, Wang L.   +8 more
europepmc   +1 more source

Chronic Kidney Disease in Metabolic Disease: Regulation of SGLT2 and Transcriptomic-Epigenetic Effects of Its Pharmacological Inhibition. [PDF]

Int J Mol Sci
Salvà C, Kaser S, Landolfo M.
europepmc   +1 more source

Euglycemic diabetic ketoacidosis following sleeve gastrectomy in a patient with type 2 diabetes on a sodium-glucose co-transporter 2 inhibitor: a case report and call for practice guidelines. [PDF]

AME Case Rep
Alsulaimi NMA.
europepmc   +1 more source

Risk of recurrent diabetic ketoacidosis following initiation of sodium-glucose co-transporter 2 inhibitors in patients with an insulin-deficient diabetes and prior diabetic ketoacidosis: An observational cohort study. [PDF]

Diabetes Obes Metab
Tsur A, Hamtzany O, Pollack R, Cahn A.
europepmc   +1 more source

Molecular mechanisms and computational insights into human SGLTs: advancing toward selective SGLT1 inhibition. [PDF]

Front Mol Biosci
Kaijage N, Kraszewski S.
europepmc   +1 more source

Metabolic reprogramming in cancer: dysregulation of glucose, lipid, and amino acid pathways and therapeutic opportunities. [PDF]

Mol Biomed
Yu M, Yang D, Chen X, Yang Y, Zhang B, Jiang X, Xing L, Yang Y, Sun Y, Li N.   +9 more
europepmc   +1 more source

Sodium-glucose co-transporter inhibitors, refractory hypomagnesaemia and recurrent genital mycotic infections. [PDF]

Clin Kidney J
Shah CV.
europepmc   +1 more source

Effects of different dosages of Sodium-glucose cotransporter 2 inhibitors on glucose level change in patients with type 2 diabetes stratified by HbA1c and renal function: a systematic review and meta-analysis. [PDF]

Front Endocrinol (Lausanne)
Xiong R, Yang Y, Li Y, Zhang H.
europepmc   +1 more source